Baseline characteristics of patients who received ven/aza or IC
| Variable . | Ven/aza (n = 143) . | IC (n = 149) . | P (IC vs ven/aza) . |
|---|---|---|---|
| Sex | .1168* | ||
| Male | 72 (50.4) | 78 (52.3) | |
| Female | 71 (49.6) | 71 (47.7) | |
| Median age (range), y | 69.5 (22-91) | 52.7 (19-81) | <.0001†‡ |
| Median bone marrow blast (range), % | 50.3 (10-96.5) | 55.7 (10.5-95.5) | .0639‡ |
| FAB M0/M1 | 87 (60.8) | 63 (42.3) | .0015*† |
| FAB M5 | 14 (9.8) | 19 (12.7) | .4243* |
| KMT2A rearranged | 7 (4.9) | 13 (8.8) | .1954* |
| ELN risk group | <.0001*† | ||
| Adverse | 93 (65.0) | 60 (40.3) | |
| Favorable | 24 (16.8) | 23 (15.4) | |
| Intermediate | 24 (16.8) | 24 (16.1) | |
| Unable to assess | 2 (1.4) | 42 (28.2) | |
| FLT3 ITD | 20 (14.0) | 40 (29.2) | .0019*† |
| NPM1 mutation | 33 (23.1) | 42 (31.3) | .1218* |
| NPM1 mutation + age ≥65 y | 25 (17.5) | 8 (5.4) | <.0001*† |
| IDH mutation | 39 (27.3) | 24 (21.4) | .2829* |
| IDH1 mutation | 15 (10.5) | 7 (6.4) | .2571* |
| IDH2 mutation | 24 (16.8) | 18 (16.1) | .8791* |
| RAS pathway mutation | 26 (18.3) | 11 (14.3) | .4479* |
| TP53 mutation | 25 (17.4) | 4 (5.2) | .0107*† |
| ASXL1 mutation | 36 (25.3) | 11 (14.3) | .0568* |
| Splice gene mutation | 50 (35.2) | 10 (13.0) | .0004*† |
| RUNX1 mutation | 23 (16.2) | 10 (13.0) | .5260* |
| RUNX1 mutation + age ≥65 y | 20 (14.0) | 2 (1.3) | .0002*† |
| Secondary AML | 59 (41.3) | 42 (28.2) | .0189*† |
| Treatment-related AML | 27 (18.9) | 15 (10.1) | .0319*† |
| Prior therapy for MDS or MPN | 17 (11.9) | 15 (10.1) | .6185* |
| Allogeneic stem cell transplantation | 31 (23.1) | 110 (74.8) | <.0001*† |
| Variable . | Ven/aza (n = 143) . | IC (n = 149) . | P (IC vs ven/aza) . |
|---|---|---|---|
| Sex | .1168* | ||
| Male | 72 (50.4) | 78 (52.3) | |
| Female | 71 (49.6) | 71 (47.7) | |
| Median age (range), y | 69.5 (22-91) | 52.7 (19-81) | <.0001†‡ |
| Median bone marrow blast (range), % | 50.3 (10-96.5) | 55.7 (10.5-95.5) | .0639‡ |
| FAB M0/M1 | 87 (60.8) | 63 (42.3) | .0015*† |
| FAB M5 | 14 (9.8) | 19 (12.7) | .4243* |
| KMT2A rearranged | 7 (4.9) | 13 (8.8) | .1954* |
| ELN risk group | <.0001*† | ||
| Adverse | 93 (65.0) | 60 (40.3) | |
| Favorable | 24 (16.8) | 23 (15.4) | |
| Intermediate | 24 (16.8) | 24 (16.1) | |
| Unable to assess | 2 (1.4) | 42 (28.2) | |
| FLT3 ITD | 20 (14.0) | 40 (29.2) | .0019*† |
| NPM1 mutation | 33 (23.1) | 42 (31.3) | .1218* |
| NPM1 mutation + age ≥65 y | 25 (17.5) | 8 (5.4) | <.0001*† |
| IDH mutation | 39 (27.3) | 24 (21.4) | .2829* |
| IDH1 mutation | 15 (10.5) | 7 (6.4) | .2571* |
| IDH2 mutation | 24 (16.8) | 18 (16.1) | .8791* |
| RAS pathway mutation | 26 (18.3) | 11 (14.3) | .4479* |
| TP53 mutation | 25 (17.4) | 4 (5.2) | .0107*† |
| ASXL1 mutation | 36 (25.3) | 11 (14.3) | .0568* |
| Splice gene mutation | 50 (35.2) | 10 (13.0) | .0004*† |
| RUNX1 mutation | 23 (16.2) | 10 (13.0) | .5260* |
| RUNX1 mutation + age ≥65 y | 20 (14.0) | 2 (1.3) | .0002*† |
| Secondary AML | 59 (41.3) | 42 (28.2) | .0189*† |
| Treatment-related AML | 27 (18.9) | 15 (10.1) | .0319*† |
| Prior therapy for MDS or MPN | 17 (11.9) | 15 (10.1) | .6185* |
| Allogeneic stem cell transplantation | 31 (23.1) | 110 (74.8) | <.0001*† |